Dong Xian-Zhe, Wang Dong-Xiao, Zhang Tian-Yi, Liu Xu, Liu Ping, Hu Yuan
Department of Clinical Pharmacology and Pharmacy, Center of Pharmacy, Chinese PLA General Hospital; Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China.
Department of Clinical Pharmacology and Pharmacy, Center of Pharmacy, Chinese PLA General Hospital, Beijing, China.
Neural Regen Res. 2020 Feb;15(2):302-310. doi: 10.4103/1673-5374.265555.
Kai-Xin-San consists of Ginseng Radix, Polygalae Radix, Acori Tatarinowii Rhizoma, and Poria at a ratio of 3:3:2:2. Kai-Xin-San has been widely used for the treatment of emotional disorders in China. However, no studies have identified the key proteins implicated in response to Kai-Xin-San treatment. In this study, rat models of chronic mild stress were established using different stress methods over 28 days. After 14 days of stress stimulation, rats received daily intragastric administrations of 600 mg/kg Kai-Xin-San. The sucrose preference test was used to determine depression-like behavior in rats, while isobaric tags were used for relative and absolute quantitation-based proteomics to identify altered proteins following Kai-Xin-San treatment. Kai-Xin-San treatment for 2 weeks noticeably improved depression-like behaviors in rats with chronic mild stress. We identified 33 differentially expressed proteins: 7 were upregulated and 26 were downregulated. Functional analysis showed that these differentially expressed proteins participate in synaptic plasticity, neurodevelopment, and neurogenesis. Our results indicate that Kai-Xin-San has an important role in regulating the key node proteins in the synaptic signaling network, and are helpful to better understand the mechanism of the antidepressive effects of Kai-Xin-San and to provide objective theoretical support for its clinical application. The study was approved by the Ethics Committee for Animal Research from the Chinese PLA General Hospital (approval No. X5-2016-07) on March 5, 2016.
开心散由人参、远志、石菖蒲和茯苓按3:3:2:2的比例组成。开心散在中国已被广泛用于治疗情绪障碍。然而,尚无研究确定与开心散治疗反应相关的关键蛋白。在本研究中,采用不同的应激方法在28天内建立慢性轻度应激大鼠模型。在应激刺激14天后,大鼠每天接受600mg/kg开心散灌胃给药。采用蔗糖偏好试验来测定大鼠的抑郁样行为,同时使用等压标签进行基于相对和绝对定量的蛋白质组学分析,以鉴定开心散治疗后改变的蛋白质。开心散治疗2周可显著改善慢性轻度应激大鼠的抑郁样行为。我们鉴定出33种差异表达蛋白:7种上调,26种下调。功能分析表明,这些差异表达蛋白参与突触可塑性、神经发育和神经发生。我们的结果表明,开心散在调节突触信号网络中的关键节点蛋白方面具有重要作用,有助于更好地理解开心散的抗抑郁作用机制,并为其临床应用提供客观的理论支持。该研究于2016年3月5日获得中国人民解放军总医院动物研究伦理委员会批准(批准号:X5-2016-07)。